Salute e Benessere

Active Pharmaceutical Ingredient (API) Market Size, Share & Growth Report…

Active Pharmaceutical Ingredient (API) Market Size, Share & Growth Report 2025-2034
Cervicorn Consulting
30/05/2025

Clinical Trials Market Size & Share Report - 2025 to 2034

Cervicorn Consulting
30/05/2025

BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT…

Consolidation Consolidation The Company currently has 293,425,203 Common Shares issued and outstanding, and it is anticipated that immediately following the Consolidation, excluding Common Shares to be issued in connection with this Offering, the Company will have approximately 29,342,520 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. The exercise or conversion price of the Company's convertible securities and the number of Common Shares...
PR Newswire
30/05/2025

Isotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark…

Cardirad, a leading distributor of healthcare products in the region, will ensure that Isoprotrace® is readily accessible to medical facilities across Sweden and Denmark. "We are proud to partner with Isotopia to bring this innovative diagnostic solution to clinicians and patients in the Nordic region," said John Storbjörk, President at Cardirad. "Isoprotrace® provides healthcare professionals with a valuable tool to improve diagnostic accuracy and optimize patient care in…
PR Newswire
30/05/2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with…

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study$20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, British Columbia, May30, 2025(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage...
Nasdaq GlobeNewswire
30/05/2025

Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik

Introduced to a global audience through exclusive live demonstrations, Alma IQ, redefines how practitioners and patients approach aesthetic care from the very first consultation. By delivering real-time, high-definition insights beneath the skin's surface, the platform reveals what the eye cannot see, empowering aesthetic professionals to make informed decisions with unprecedented precision. Introduced to a global audience through exclusive live demonstrations, Alma IQ, redefines how...
PR Newswire
30/05/2025

Highlights of ESHG | Rapid AI Karyotype Total Solution From China Makes a Big…

During the conference, Professor Liang Desheng from the Center for Medical Genetics at Central South University in China presented a poster titled "iMedImage®: an end-to-end foundational model for medical image recognition and its application in chromosome analysis." Karyotyping, the gold standard for detecting chromosomal abnormalities, remains critical for diagnosing genetic and hereditary diseases. While AI effectively identifies numerical abnormalities, detecting structural…
PR Newswire
30/05/2025

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data…

Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 monthsSurvival has currently reached plateau, with 34% (7/20) of patients still alive 80% of patients treated with EO4010/nivolumab showed specific immune responses against tumor associated antigens targeted by the OncoMimics™ immunotherapyEO4010 continues to demonstrate excellent safety and tolerabilityData support further development of EO4010 to...
Nasdaq GlobeNewswire
30/05/2025

EssilorLuxottica to acquire Optegra clinics, another leap forward in its…

EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance the Group's development of the most comprehensive and digital-forward patient journeyParis, France and London, United Kingdom (30 May 2025)– EssilorLuxottica and MidEuropa announced today they entered into an agreement for EssilorLuxottica to acquire Optegra, a fast-growing and highly integrated ophthalmology platform...
Nasdaq GlobeNewswire
30/05/2025

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3…

Itepekimab met the primary endpoint in one of two COPD phase 3 studiesAERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefitAERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the studyItepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2Sanofi and...
Nasdaq GlobeNewswire
30/05/2025

Roche's fenebrutinib maintains near-complete suppression of disease activity and…

Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatmentPhase III studies for fenebrutinib in relapsing and primary progressive multiple sclerosis are expected to start reading out at year endBasel, 30 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability...
Nasdaq GlobeNewswire
30/05/2025

INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled…

Acorda Therapeutics' INBRIJA (Levodopa) Overview Acorda Therapeutics' INBRIJA (Levodopa) Overview INBRIJA is an inhalable dry powder formulation of levodopa designed for use with the INBRIJA inhaler. The medication is delivered via white hypromellose capsules, each containing 42 mg of levodopa in a spray-dried powder form, along with excipients such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride. Levodopa, the active ingredient in INBRIJA, is an aromatic amino...
PR Newswire
30/05/2025

B-Cell Inhibitors Market Poised for Significant Advances During the Forecast…

Key Takeaways from the B-cell Inhibitor Market Report Key Takeaways from the B-cell Inhibitor Market Report Discover which indication is expected to grab the major B-cell inhibitor market share @B-cell Inhibitor Market Report B-cell Inhibitor Market Dynamics The B-cell inhibitor market is undergoing significant transformation, driven by adeepening understanding of B-cell biologyand its role in awide range of immune-mediated and oncological diseases. The market is...
PR Newswire
29/05/2025

Anal Cancer Market Heats Up Following Incyte's Zynyz Greenlight | DelveInsight

Anal squamous cell carcinoma (ASCC) is the predominant type, comprising around 80–85% of anal canal cancer cases. Less frequent forms include adenocarcinomas, melanomas, and basal cell carcinomas. According to DelveInsight's analysis, there were around 20,000 new cases of anal cancer across the seven major markets in 2023, a figure projected to rise by 2034. In the United States, approximately 82% of anal cancer cases were linked to HPV, underlining it as the primary cause. Anal squamous cell...
PR Newswire
29/05/2025

Outcomes4Me Secures $21M in Funding to Accelerate AI-Driven Innovation and Drive…

With this round, Outcomes4Me welcomes new investor London-based Salica Investments, with participation from all existing investors: Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD, bringing Outcomes4Me's total capital raised to date to $38M. With this round, Outcomes4Me welcomes new investorLondon -based Salica Investments, with participation from all existing investors: Labcorp Venture Fund, Forecast Labs,...
PR Newswire
29/05/2025

Seagull Watch was honored as the "Charming China Fashion Partner" of the 78th…

During the official events of the film festival, Seagull invited industry professionals and filmgoers to wear several of its masterpieces. As the brand's leading product in the fashion line, the "Little Golden Brick" ladies' mechanical watch shone brightly with its exquisite design and simple style. The first independently developed and produced double chronograph split-seconds chronograph in China, the 1963 era version of the watch paying tribute to China's first aviation chronograph…
PR Newswire
29/05/2025

Non-Emergency Medical Transportation Market Share worth $19.9 billion, Globally…

For More Information and To Stay Updated on The Latest Developments in The Global Non-Emergency Medical Transportation Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=14929 For More Information and To Stay Updated on The Latest Developments in The Global Non-Emergency Medical Transportation Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=14929 Market Overview and Growth...
PR Newswire
29/05/2025

NLP in Healthcare & Life Sciences Market worth $16.01 billion by 2030- Exclusive…

Browse in-depth TOC on "NLP in Healthcare & Life Sciences Market" Browse in-depth TOC on "NLP in Healthcare & Life Sciences Market" 285 – Tables61 - Figures 395 – Pages Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131821021 Scope of the Report Clinical operations & decision support will register the largest market share during the forecast period The clinical operations and decision support application of NLP in healthcare...
PR Newswire
29/05/2025

Press Release: Beyfortus public health advantage bolstered by first real-world…

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK following RSVpreF-only maternal vaccination Newly presented durability data show Beyfortus sustained efficacy of 83% through six months in babies born before or during the RSV...
Nasdaq GlobeNewswire
29/05/2025

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration…

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led byAUSTEDO ®(deutetrabenazine), AJOVY ®(fremanezumab), UZEDY ®(risperidone) andlate-stage pipeline with blockbuster potentialReaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and PARSIPPANY, N.J., May29, 2025(GLOBE NEWSWIRE) -- Teva...
Nasdaq GlobeNewswire
29/05/2025

NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in…

The poster titled, "A Phase Ib Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of the Novel Neuroplastogen DLX-001 in Participants with Major Depressive Disorder: Interim Findings," was presented by Aaron Koenig, MD, Chief Medical Officer at Delix Therapeutics and featured data confirming the Cumulus NeuLogiq® Platform detected a pharmacodynamic signal consistent with that previously observed in a phase I healthy volunteer study. A consistent increase in slow-wave…
PR Newswire
29/05/2025

Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence

The FDA inspection, conducted with meticulous detail, evaluated Medicilon's organizational structure, personnel qualifications, SOPs, facilities integrity, documentation processes, experimental operations, quality assurance systems, and computerized infrastructures. Inspectors also reviewed several research projects submitted to the FDA. The FDA inspection, conducted with meticulous detail, evaluated Medicilon's organizational structure, personnel qualifications, SOPs, facilities integrity,...
PR Newswire
29/05/2025

Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners…

Its precision-engineered capabilities make it the ideal choice for practitioners seeking transformative results with minimal downtime, reduced patient discomfort and speedy healing. Complementing UltraClear, the AuraLux laser leverages the same exclusive Cool Pulse™ technology and broadens accessibility for aesthetic providers and their patients while maintaining Acclaro's hallmark quality. Its precision-engineered capabilities make it the ideal choice for practitioners seekingtransformative...
PR Newswire
29/05/2025

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in…

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May29, 2025(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a...
Nasdaq GlobeNewswire
29/05/2025
Altri  Comunicati